TY - JOUR AU - Benlmouden, Amine AU - Billaud, Eliane PY - 2016/01/30 Y2 - 2024/03/29 TI - Evidence Based Digoxin Therapeutic Monitoring - A Lower and Narrower Therapeutic Range JF - Integrative Journal of Medical Sciences JA - Integr J Med Sci VL - 3 IS - SE - REVIEWS DO - 10.15342/ijms.v3i1.87 UR - https://mbmj.org/index.php/ijms/article/view/36 SP - 22-25 AB - <p>Cardiac glycosides have been used for congestive heart failure and certain cardiac arrhythmias for more than 200 years. Despite introducing a variety of new classes of drugs for the management of heart failure, specifically angiotensin-converting enzyme (ACE) inhibitors, b-adrenergic antagonists (blockers), and the aldosterone antagonist spironolactone, digoxin continues to have an important role in long-term outpatient management. However, a narrow margin exists between therapeutic and toxic doses of digoxin, resulting in a high incidence of digoxin toxicity in clinical practice.</p><p>A wide variety of placebo-controlled clinical trials have unequivocally shown that treatment with digoxin can improve symptoms, quality of life, and exercise tolerance in patients with mild, moderate, or severe heart failure. The clinical relevance of digoxin therapeutic monitoring is also proved but the SDC (Serum Digoxin Concentrations) required for optimal clinical efficacy and acceptable toxicity remains controversial. In the last years, international guidelines recommend 1.2 ng/mL as an acceptable high level.</p><p>In this bibliographic synthesis, we aim to collect pertinent information from the MedLine database about an exposure-effect relationship to assess the evidence level scientific of new digoxin therapeutic monitoring.</p> ER -